Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Intel Corporation (INTC) -- Ignore unavailable to you. Want to Upgrade?

To: Brian Malloy who wrote (100872)	3/15/2000 1:23:00 AM
From: Scumbria	Respond to of 186894

In an interview, Incyte Chief Executive Roy Whitfield applauded what he called Clinton's "strong endorsement" of intellectual property protection. He also expressed the conviction, as did the executives of several other companies, that their patent filings will meet new criteria established by the Patent and Trademark Office, which recently made requirements for patents more stringent. ?Incyte has by far and away the leading patent portfolio,? Whitfield said. He also said the reaction Tuesday in the marketplace was excessive. "The stocks are being hit because investors have not yet figured out how to discriminate among genomics companies," Whitfield said. Human Genome Sciences Chief Executive William Haseltine said it was in fact a "good day for biotechnology" because President Clinton outlined his stance on patent protection more clearly. "It?s the first time the President is on record," Haseltine said. He too said the sell-off was an overreaction, due to a "dim understanding of genes" and a "dim understanding of patents. The combination of the two,? Haseltine said, "must be utterly confusing to investors." Haseltine also expressed confidence that Human Genome Sciences patent portfolio can meet the new standards. "The patents we file meet these criteria," he said. GeneLogic President Mark Gessler said he agreed with Blair's and Clinton's assertion that fundamental genetic data should be in the public domain, as well as their view that companies are free to file patents on the discoveries they make. "We?re in full support of their views," Gessler said. cbs.marketwatch.com Scumbria